Back to BAYRYView full pipeline
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Multiple Sclerosis, Relapsing-Remitting
View Full LandscapeDrug Information
Target Indication
Multiple Sclerosis, Relapsing-Remitting
Clinical Trial
NCT03910738Last updated: 9/10/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Developer
Related Pipeline
FondaparinuxPhase 3
Superficial Vein Thrombosis
aflibercept 8 mgPhase 3
Polypoidal Choroidal Vasculopathy
Levofloxacin & MetronidazolePhase 3
Pelvic Inflammatory Disease
Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & RifampicinPhase 3
Pulmonary Tuberculosis
meropenem, moxifloxacinPhase 3
Severe Sepsis
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts